Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Dillon & Associates Inc.

Dillon & Associates Inc. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,899 shares of the biopharmaceutical company’s stock after buying an additional 374 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.4% of Dillon & Associates Inc.’s holdings, making the stock its 24th biggest position. Dillon & Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,896,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in REGN. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on REGN. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Piper Sandler decreased their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $658.48 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a 50-day moving average price of $689.43 and a 200 day moving average price of $813.15. The stock has a market cap of $71.99 billion, a PE ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company earned $11.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.